A lzheimer's disease (AD) is the most common type of dementia (1,2) and is characterized by cognitive deficits and behavioural and psychological symptoms. These behavioural and psychological symptoms of dementia (BPSD) include delusions, hallucinations, aggression, aberrant motor behaviour, sleep disruptions, agitation, depression, and apathy (3,4). Research in the pathobiology of AD has revealed a gross disruption of neurotransmitter systems (5), including the cholinergic (4) and serotonergic (6,7) systems in both cortical and subcortical areas of the brain. Although deficits in the cholinergic system have been associated with both cognitive changes (8) and BPSD (4,9), manipulation of the cholinergic system has limited effectiveness. Hence, attention has turned to other possible therapeutic targets for patients with AD.
GABA Pharmacology
GABA is synthesized from glutamate by the enzyme glutamic acid decarboxylase (GAD) and is metabolized by the enzyme GABA-transaminase (GABA-T), whereby GABA released into nerve terminals is converted to succinic acid semialdehyde (28) . The GABA receptor has been postulated to be a heterooligomeric glycoprotein with 5 or more transmembrane units. To date, 3 subtypes of GABA-specific receptors have been identified: GABA A , GABA B , and GABA C (29) . Both GABA A and GABA B receptors are localized in the central nervous system (CNS). GABA C is specific for the retina (30) and will not be discussed here.
The GABA A receptor is the most extensively studied of the 3 receptor types. It comprises a combination of receptor subunits and is a heterooligomeric formation of alpha 1 to 6, beta 1 to 4, and gamma 1 to 4 (30); delta and epsilon (29, 31) ; theta (32) ; or pi subunits (33) . Therefore, an enormous array of subtype combinations may exist, but for a fully functional GABA A receptor, it appears that an alpha, a beta, and 1 other subunit type, such as gamma, delta, or epsilon, are required (29, 33) . The alpha-beta-gamma subunit containing receptors are categorized as GABA A1 to GABA A6 , according to the alpha subunit present (30) . Found on both pre-and postsynaptic neurons, the GABA A receptor is a ligand-gated ion channel that is connected to many other neurons, such as dopamine and serotonin. GABA A receptors containing the alpha 1 subunit are responsive to all hypnotic drugs (34) . When bound by GABA agonists, GABA A receptors increase the flux of chloride ions, which in turn causes hyperpolarization of neurons (26) . In this way, GABA A receptors reduce synaptic transmission of dopamine, serotonin, and acetylcholine. In patients with AD, postsynaptic GABA A receptors elevate interstitial GABA caused by the conversion of glutamate to GABA by GAD, resulting in chronic depolarization and neuronal degeneration (35) . In addition to a GABA-agonist binding site, the GABA A receptor has sites specific for benzodiazepines, barbiturates, steroids, and ethanol (26) . The high-affinity binding of benzodiazepines, such as diazepam, is conferred by the 2 subunit and adjacent alpha 1 , alpha 2 , alpha 3 , or alpha 5 subunits (33) , with the alpha subunit being a key determinant of the benzodiazepine pharmacology (31, 36) . Evidence has shown that agonist binding to these other sites enhances GABA's inhibitory effects. Therefore, any disruption in individual binding sites, or in the receptor as a whole, may also alter the The Canadian Journal of Psychiatry-Special Geriatric Psychiatry Section Mediates anxiolytic (143) properties of diazepam (in monoaminergic system) (144) 4
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Each GABA A receptor subtype has specific properties, and research is beginning to illuminate the function of the various individual receptor subunits as well (Table 1) . Research in this area is becoming increasingly complex because different combinations of receptor units produce receptor subtypes with varying characteristics. Much remains to be learned about the GABA A receptor subtype subunits.
The GABA B receptor is not widely distributed in the brain, compared with GABA A (26) . GABA B is linked to G proteins and a second-messenger system that mediates calcium or potassium channels, producing slow inhibitory postsynaptic potentials in several brain regions (29) . GABA B receptors are heterooligomeric and are made up of a GABA B R1a or GABA B R1b subunit and a GABA B R2 subunit (29) . Although both receptors bind GABA, GABA B is not modulated by benzodiazepines, barbiturates, or steroids, unlike GABA A (29) . Instead, it is distinguished from GABA A through selective affinity for baclofen (37) . Recent evidence in animal studies suggests that GABA B may be linked to cognition (38) .
In summary, there are 2 main types of GABA receptors in the CNS: GABA A and GABA B , both of which have many subtypes. The GABA A receptor is both pre-and postsynaptic; is widely distributed; and has modulatory sites specific for benzodiazepines, barbiturates, steroids, and ethanol. GABA B is also found both presynaptically (that is, on autoreceptors and glutamate neurons, which inhibit neurotransmitter release) and postsynaptically (for example, in the hippocampus), which decrease neuronal excitability and may be linked to cognition.
Evidence for GABAergic Dysfunction in AD
There are 4 lines of evidence that evaluate the possibility of disruptions in the GABAergic system in AD: postmortem studies, antemortem studies, neuroimaging studies, and markers of CNS GABA.
Although riddled with limitations, postmortem studies in AD comprise the bulk of evidence attempting to establish altered GABA in patients with AD. There are 22 studies in the medical literature examining GABA concentration and GABA benzodiazepine binding in AD patients, compared with control subjects . These postmortem investigations include, first, studies measuring GABA concentrations (39 49,59,60) ; and second, GABA receptor ligand-binding studies that use GABA-specific ligands (61) (62) (63) (64) , the GABA A specific agonist muscimol (51, 55, 65) , or benzodiazepines (51) (52) (53) (54) (55) (56) (57) (58) . Postmortem studies on cortical areas have, for the most part, shown that the frontal (24% to 29%), temporal (19% to 47%), and parietal (21% to 47%) regions may have reduced GABA concentration in AD (Table 2) . Binding studies using GABA or benzodiazepines (Table 3) suggest that the temporal region is affected in AD patients. The limbic regions that appear to have reduced GABA in patients with AD include the cingulate (26% to 36%), amygdala (17% to 28%), and thalamus (28% to 36%) ( Table 2) . GABA in the hippocampus, caudate, putamen, and nucleus accumbens does not appear to be affected by AD, though there have been some positive results found within the hippocampus and caudate (Tables 2 and 3) . GAD and GABA-T have also been measured centrally postmortem. GAD is located only within neurons and can therefore be used as a marker for GABA localization in the brain. GABA-T is the enzyme responsible for GABA degradation in the brain. Potential alterations in GABA-T in AD patients may reflect differences in the rate at which GABA undergoes catabolism. Five studies have examined GAD activity in AD patients postmortem (66) (67) (68) (69) (70) . Despite differing methodologies and design issues, studies suggest decreased GAD activity with compensatory increases in mRNA expression. Three studies that have examined whether GABA-T activity is altered in AD patients show a possible disease-dependent effect of AD on GABA-T activity (71) (72) (73) . Most postmortem studies are limited by differing postmortem delays, lack of control for AD severity, and concomitant use of psychotropic medications. Overall, the postmortem studies in AD suggest that GABA concentrations are decreased in cortical areas of the brain with decreasing GAD activity. In addition, limbic areas are varyingly affected by a decrease in GAD activity.
Given the limitations of interpreting postmortem tissue analysis, antemortem studies should be of greater value in determining neurotransmitter concentration among patients with AD. Two of the 3 studies are negative (41, 74) , and the third reports increased GABA in the frontal cortex (42) . The ability to draw conclusions from the antemortem data is limited by the small number of patients, the absence of disease severity reports, and confounding by concomitant medications.
Imaging techniques, such as positron emission tomography (PET) and single photon emission tomography (SPECT), provide a visual means of identifying cortical and subcortical GABA deficiencies. To date, 5 studies have used neuroimaging to identify potential changes in GABA neurons in AD patients ( I-iomazenil (a high-affinity benzodiazepine antagonist) found significant reductions in binding in the parietal cortex (76, 79) in AD patients, compared with non-AD patients. with the brain and, therefore, may contain endogenous chemical constituents found in cortical and subcortical areas. Of 12 published studies (Table 5 ) (80-91), only 4 found significant reductions (40% to 77%) in CSF GABA among AD patients, compared with control subjects (88) (89) (90) (91) . Although GABA cannot cross the blood-brain barrier, some investigators have considered whether GABA concentrations are altered in the plasma of patients with AD. Of 3 studies in the medical literature, 1 found AD patients to have a significant reduction in GABA (51%) (80), and 2 (81,82) were unable to detect a significant difference. The validity of these markers remains uncertain.
Of the studies mentioned, 2 described BPSD. Procter and colleagues matched for age, autopsy delay, and brain storage time 17 patients with AD and 18 patients with no dementia (50) . Areas of interest included the frontal, temporal, and parietal cortices in both groups. Aggression was the behaviour of interest and was determined qualitatively through retrospective chart reviews and correspondence with caregivers up to 6 months antemortem. The authors reported no significant differences in GABA concentration between AD patients and control subjects with or without behaviours in all brain areas. However, only 1 or 2 patients with aggression for each brain area were analyzed. It must be noted that, owing to the effect of the agonal state, the authors used samples from patients with protracted illness (that is, 7 AD patients and 10 control patients). Wyper and colleagues provided the single imaging study that reported on behaviours among the patients studied.
Of the 6 patients, 2 were qualitatively determined to have ideational and dressing apraxis, paranoid delusions, and irritability, respectively (79) . Unfortunately, owing to the small sample size, the authors were unable to correlate behaviours with affected regions. Results did not reach significance. All percentages represent % change in AD samples, compared with control subjects; AD = subjects with Alzheimer 's disease, C = control subjects; DC = control subjects with dementia; M = men; W = women; increase;¯decrease; « no change; AChE = acetyltransferase; ChAT = choline acetyltransferase; CNS = central nervous system; -= unknown In summary, 4 lines of evidence evaluate the possibility of disruptions in the GABAergic system in AD: postmortem studies, antemortem studies, neuroimaging studies, and markers of CNS GABA. Neuroimaging techniques are consistent with postmortem studies in finding large variations in the presence and extent of changes in GABA. In general, more extensive cortical involvement was demonstrated in the postmortem analyses (likely showing predominantly advanced AD), and more limited cortical involvement was demonstrated in the neuroimaging studies (likely showing earlier AD). Involvement of the limbic system was more variable, which is consistent with its role in BPSD. Disruptions in the GABAergic system have not yet been linked with specific BPSD.
Clinical Use of GABAergic Agents in Dementia
The GABA receptor comprises various binding sites for GABA, benzodiazepines, barbiturates, and steroids. Each of these sites may be involved in the regulation of GABAergic neurons with respect to its inhibitory effects on other neuronal systems. Administration of exogenous agents that bind specifically to each site on the GABA receptor may be useful in producing or inhibiting typical GABA-related phenotypes, such as anxiety, aggression, and sleep.
GABA Receptor Ligands
In addition to endogenous GABA affecting ion flux, several exogenous ligands bind specifically to the GABA-receptor site only with agonistic (that is, muscimol and baclofen) or antagonistic (that is, bicuculline and picrotoxin) properties. However, very little data concerning the use of these agents among patients with AD have been collected. To determine its effect on cognitive function, Mohr and colleagues reported on the use of GABA agonist 4,5,6,7-tetrahydroisoxazolo [5,4,-c]pyridin-3-ol (THIP) among 6 AD patients, compared with 6 AD patients taking placebo, (88) . They reported no significant change on 6 neuropsychological tests with THIP. Behaviours were not ascertained in the study. 
Benzodiazepine Receptor Ligands
The benzodiazepine class of drugs has been used for many years to reduce anxiety and promote sleep among the population with no dementia. Unfortunately, these agents may produce tolerance after long-term use, as well as other side effects such as sedation, dizziness, and ataxia. Therefore, there is a concern with benzodiazepine use among the elderly, especially since these patients have altered pharmacokinetic and pharmacodynamic features that may limit therapy. Stahl and colleagues have shown that a large proportion of AD patients receiving donepezil also receive hypnotics for the management of behavioural symptoms (92) . There have been many published reports in the medical literature concerning benzodiazepine use to manage behaviours in patients with AD and associated dementias.
Alprazolam, a short-to intermediate-acting benzodiazepine agonist, has not been extensively studied among the psychogeriatric population. In a randomized trial, Ancill and colleagues (93) compared alprazolam to lorazepam in dementia patients with agitation. The authors did not find significant differences in the 2 medication groups with respect to efficacy, but they did report that lorazepam was associated with more adverse events. In a multicentre, randomized, controlled crossover trial, Christensen and colleagues compared alprazolam to haloperidol in treating agitation and behavioural disorders associated with dementia (94) . Forty-eight patients who completed the full protocol were found to be no different, whether they received alprazolam or haloperidol, regarding the number of behavioural episodes, activities of daily living, or clinical global impression (CGI). These results did not change when patients were stratified for severity of cognitive impairment and behavioural episodes. Although the number of dropouts in each group did not differ, one-third of the participants did not complete the full protocol.
Clonazepam is a high-potency benzodiazepine with specific affinity for the benzodiazepine receptor. To date, there are no randomized controlled trials (RCTs) examining clonazepam effectiveness in treating BPSD. Smeraski reported on a case wherein clonazepam was used in conjunction with thioridazine to treat agitation, hostility, and combativeness in a 63-year-old inpatient diagnosed with multiple-infarct dementia (95) . Within 24 hours of clonazepam administration, the patient had improvement in agitation and combativeness, which was maintained on 4 mg daily of clonazepam. In another case report by Freinhar and Alvarez, the authors found successful treatment of violent behaviour and agitation in 2 elderly patients with organic brain syndromes (96) . Ginsburg reported on the cases of 6 consecutive AD patients presenting with agitated and aggressive behaviour who were treated with low-dosage clonazepam (97) . Four of the 6 patients showed improvement in behaviour, and sedation was the most common dose-limiting adverse event. In a prospective observational cohort study, Calkin and colleagues identified 24 inpatients treated with clonazepam (mean dosage 1.2 mg) over a 21-month evaluation period to determine whether the drug improved behaviours and was associated with greater severity of adverse events (98) . Patients diagnosed with dementia (n = 16) showed no significant improvement in behaviours (as measured by the Brief Psychiatric Rating Scale [BPRS] and the Cohen-Mansfield Agitation Inventory), but were found to have less frequent side effects and showed global improvements. Importantly, clonazepam was not associated with significant decline in cognitive functions, as determined by Mini-Mental State Exam (MMSE) scores.
Because of the various active metabolites produced, diazepam is a long-acting benzodiazepine. Only 2 clinical trials have been conducted using diazepam to treat BPSD. In both reports, diazepam was compared with thioridazine in a double-blind, randomized fashion (99,100). Both investigators reported significant improvement in behavioural symptoms for both agents, though thioridazine produced slightly greater improvement and diazepam was found to produce tolerance over time.
Lorazepam is a commonly used benzodiazepine among the geriatric population (101). Fritz and Stewart reported on the successful use of lorazepam for the treatment of resistive aggression in 2 patients diagnosed with dementia (102) . Except for the aforementioned study comparing lorazepam with alprazolam (93), only 2 other studies exist in the medical literature. In a randomized, placebo-controlled trial examining the effectiveness of lorazepam in managing chronic behaviours among patients with probable mild-to-moderate AD (n = 10), the AD patients showed a significant trend toward BPSD improvement with lorazepam treatment, compared with age-matched subjects with no AD or BPSD (n = 10) (103). Meehan and colleagues reported a significant improvement in acute BPSD with intramuscular lorazepam treatment, compared with those treated with placebo in a double-blind, randomized study. This effect became apparent 60 minutes following lorazepam administration and was maintained for 2 hours. After 24 hours, the change in the lorazepam group was no longer significant (104) . The only significant adverse events noted with lorazepam use among AD patients were drowsiness and dry mouth.
Oxazepam, a short-acting active metabolite of diazepam, has been used in several investigations to control BPSD. The earliest studies were published in the mid-1960s by 3 independent authors examining the effectiveness of oxazepam, compared with placebo, in over 300 elderly patients (105) (106) (107) . The authors found oxazepam to be superior to placebo; however, such study limitations as lack of diagnostic criteria and lack of qualitative efficacy reports make it difficult to draw definitive conclusions. In an 8-week RCT, Coccaro and colleagues compared oxazepam (n = 19, mean dosage 30 mg) with haloperidol (n = 20, mean dosage 1.5 mg) and diphen-hydramine (n = 20, mean dosage 81.3 mg) among patients diagnosed with dementia (108) . Although all 3 groups showed significant improvements in BPSD and activities of daily living, both haloperidol and diphenhydramine had a greater nonsignificant trend toward improvement in BPSD, compared with oxazepam. The study was limited by the absence of a placebo-control group and enrollment of patients with moderate-to-severe cognitive impairment. Herz and others published the only other study using oxazepam to control behaviours in patients with dementia (109) . The authors used a single-case study approach to determine the efficacy of various agents in managing resistive behaviours in patients diagnosed with probable AD. Ten patients were randomly administered each of the following 4 trial medications in double-blind fashion for 19 weeks: 10 mg of oxazepam 3 times daily, 1 mg of thiothixene 3 times daily, 25 mg of diphenhydramine 3 times daily, and placebo. Ratings of effectiveness in managing resistance determined whether a patient was switched to a new medication. Of the patients who showed improvement in resistive score, thiothixene was effective in 5 patients, oxazepam in 2 patients, and diphenhydramine in 1 patient. The study was limited by the fact that the treatment strategy did not consider changes in the patients' disease over time and did not examine the effect of the medications on potential concurrent behaviours.
Zolpidem, a nonbenzodiazepine hypnotic, binds specifically to the benzodiazepine alpha 1 receptor and, therefore, has anxiolytic properties. Shelton and Hocking (110) reported on 2 cases of patients diagnosed with AD who were treated with zolpidem for severe sleep disturbance and nighttime wandering. Doble reported that receptors containing the alpha 1 subunit only responded to zolpidem and that any other alpha subtypes do not (34) . Both patients, who were previously nonresponsive to antipsychotics, showed positive improvements in sleep promotion without untoward effects. Shelton and colleagues reported on zolpidem being used to restore normal sleep patterns among patients with dementia, and slight behavioural improvement was also noted (110) . No other data have been published regarding zolpidem use for managing BPSD in patients with AD.
In summary, though many of the benzodiazepines lack controlled clinical trials, from the evidence to date, benzodiazepines seem to be useful in managing BPSD. The primary concern with these agents is the potential for adverse events, which may be augmented in an elderly population and are owing to pharmacologic changes. A recent study by Fastbom and colleagues suggests that benzodiazepines may have a protective effect against AD through potentiation of GABA transmission leading to increased glutaminergic inhibition (111) . This has yet to be substantiated.
Anticonvulsants
The anticonvulsants carbamazepine, gabapentin, lamotrigine, valproate, and divalproex have traditionally been used to treat epilepsy and several neuropsychiatric illnesses, including bipolar disorder, acute mania, panic, and depression. The putative mechanism of action for these agents, though not completely clear, may be according to direct or indirect modulation of GABAergic transmission. Their role in the management of BPSD has been reported in few RCTs; however, many open-label studies and case reports have highlighted the potential of anticonvulsants for treating behaviours such as agitation.
Nine reports have been published in which open-label carbamazepine was administered among 101 elderly patients with various diagnoses (for example, AD, vascular dementia, and trauma) (112) (113) (114) (115) (116) (117) (118) (119) (120) . Of the 9 authors, 5 reported patients' response to carbamazepine as being good to excellent (112) (113) (114) (115) (116) ; response was defined qualitatively as a reduction in various behaviours including aggression, agitation, irritability, and (or) impulsivity. Dosages varied from 100 mg daily to 1000 mg daily, with carbamazepine serum concentrations ranging from 1.5 µg/mL to 12 µg/mL. Four of the 9 authors used a standardized scale to determine carbamazepine efficacy among 73 severe AD patients with agitated or aggressive behaviours (118-120) and 1 patient with bipolar illness and multiple-infarct dementia complicated by auditory hallucinations (117) . Dosages varied from 100 mg daily to 1000 mg daily, with carbamazepine serum concentrations ranging from 2.3 µg/mL to 9.6 µg/mL. Both Lemke and colleagues (118) and Gleason and colleagues (119) reported a significant decrease in BPSD (approximately 24%) between 4 weeks and 7 weeks posttreatment. Tariot and colleagues reported on the carbamazepine open-label extension (modal dosage 300 mg daily, serum concentration 4.7 µg/mL to 5.0 µg/mL) from an RCT of 51 AD patients (120) . Over a 12-week period, the authors reported continued improvement in BPSD and aggression. Anton and others reported a significant drop in BPSD 4 weeks posttreatment (38%) and again at 7 weeks posttreatment (56%), using dechallenge and rechallenge methodology (117) . Carbamazepine levels ranged from 4.5 µg/mL to 9.4 µg/mL. Tariot and colleagues reported on a 12-week, placebo-controlled, nonrandomized, crossover study (121) and a 6-week, randomized, parallel study (122) , which used carbamazepine (concentration 5 µg/mL to 8 µg/mL) to control BPSD. In both studies, Tariot and others found significant and robust reductions in BPSD and profound CGI improvement (64% to 77% of patients) with carbamazepine treatment. In a similar 6-week, randomized, placebo trial, Olin and others reported significantly greater CGI improvement with carbamazepine and improved hostility among 21 AD patients with agitation treated with carbamazepine (average dosage 333 mg daily) (123) .
Reports on the use of valproate divalproex for treating BPSD in AD patients are dominated by retrospective chart reviews (124) (125) (126) and reports or case series (127) (128) (129) (130) (131) (132) (133) (134) . While uncontrolled studies indicated effectiveness in treating aggression, the 3 RCTs published to date have not confirmed these benefits (135) (136) (137) . Porsteinsson and colleagues (135) assessed the efficacy of divalproex sodium in 56 patients with agitation and various forms of dementia, as defined by DSM-IV criteria. Dosages varied from 375 mg daily to 1375 mg daily, with divalproex serum concentrations ranging from 22 to 85 g/mL. The authors reported a decrease in agitation with divalproex, compared with placebo, which became a significant difference after considering several covariates. Also, 68% of patients taking divalproex and 52% of patients taking placebo showed decreased agitation as measured by CGI. A second double-blind, placebo-controlled trial of dementia patients with manic-type symptoms found that divalproex sodium (20 mg/kg daily) was associated with significant improvement in agitation and, particularly, verbal agitation (P = 0.035) (136) . However, at the higher dosages, tolerability was a problem. Only 40 (46%) of the 87 patients receiving divalproex completed the study. CGI actually favoured placebo in that study. The third randomized, placebo-controlled trial (137) of 42 patients with dementia used lower dosages for only 3 weeks and had overall negative results. Improvement was noted in restless, melancholic, and anxious behaviour, with a trend toward improvement of suspicious and dependent behaviour. In summary, the 3 RCTs show that agitation and aggression were drug-responsive symptoms, albeit in a limited number of patients. Unfortunately, at the dosages needed to achieve therapeutic effect, tolerability appears to be a concern. In fact, thrombocytopenia associated with valproate among the elderly is now being recognized as a relatively frequent side effect necessitating careful monitoring (138, 139) .
Gabapentin, an anticonvulsant with binding sites in the neocortex, limbic system, substantia nigra, thalamus, and a structure similar to GABA, has been used in the treatment of epilepsy and psychiatric disorders such as bipolar disorder and obsessive-compulsive disorder (140) . However, the literature supporting the use of gabapentin for the management of BPSD is limited. Herrmann and others examined the effectiveness and tolerability of gabapentin in an 8-week, openlabel, prospective case series design study (140) . Twelve patients with moderate-to-severe dementia (that is, AD, vascular dementia, frontotemporal dementia, and alcoholinduced dementia) and severe behavioural disorders were treated with gabapentin (mean dosage 900 mg daily). Overall, BPSD on 2 standardized scales remained unchanged. However, on the CGI it was reported that 2 patients' conditions were rated as much improved, 3 as minimally improved, 6 as unchanged, and 1 as minimally worse. The study was limited by the inclusion of patients with various dementia diagnoses. Hawkins and others reported on the cases of 22 patients enrolled in a gabapentin study (141) . They were given different dosages (100 mg to 300 mg daily), depending on their level of aggression. Overall, the average effective daily dosage was 1318 mg. They took gabapentin for varying time periods, ranging from 4 weeks to 2 years. Results showed that 17 patients achieved a CGI rating of "much improved" or "very much improved," 4 received a rating of "minimally improved," and 1 patient's behavioural symptoms remained stable. It was incidentally found that patients' cognition also improved on gabapentin, once their agitation and aggression decreased (141) . Roane and others reported on 4 studies with patients who were treated with gabapentin for agitation (142) . Of the 4 patients, 3 were successfully titrated from the starting dosage of 300 mg daily to the full peak dosage of 2400 mg daily for a period of at least 2 weeks. Aggression decreased almost 50% and clinical improvement was noted in vocal perseveration, cursing, threatening, moaning, crying, task perseverating, and hitting. MMSE scores were not found to be affected by gabapentin. Thus preliminary evidence supports a trial of gabapentin for patients who have not responded to other medications.
Conclusions
While each of the study designs has limitations, postmortem, antemortem, and neuroimaging studies, as well as studies using indirect markers of central GABA function, provide converging evidence that GABA is decreased in AD. Postmortem studies on cortical areas have, for the most part, shown reduced frontal, temporal, and parietal GABA concentrations in AD. When combined with GABA and benzodiazepine binding studies, it seems that the temporal region is most affected in AD patients. Interestingly, neuroimaging studies have not identified either the frontal or temporal region as having altered GABA among AD patients. Rather, it is the parietal cortex that seems to have reduced GABAergic binding. It can be expected that many of the postmortem studies were performed on subjects with advanced AD, while the in vivo neuroimaging studies were performed on subjects with less advanced disease. Thus, widespread involvement of the cortical regions may occur with advanced AD or reflect lack of correction for cerebral atrophy. GABA within the limbic system, which is the primary area for emotion and behaviour in the human brain, has not been shown to have ubiquitous GABA reductions. In summary, rather than defining the pathology of AD, the presence of GABAergic reductions may reflect subtypes of the disease, which is consistent with a role in BPSD that accompany AD. Few studies attempt to link BPSD with GABAergic disruptions.
Clinical experience supports GABA as a therapeutic target for symptomatic treatment of BPSD. Aggression and agitation are drug-responsive symptoms. Benzodiazepines, for example, are commonly used in clinical practice to reduce agitation and aggression exhibited by patients with dementia (101) . Although benzodiazepines such as lorazepam have been reported to work in some cases (102) , the potential therapeutic effect may be outweighed by adverse events, such as sedation (93, 103) . Other GABAergic therapies, including anticonvulsants, show greater promise in managing behaviours such as aggression but are limited by toxicity. While such newer antiepileptic drugs as vigabatrin, tiagabine, and topiramate are not free from toxicity, they offer novel mechanisms of action that involve the GABAergic system.
The role of GABA in dementia has yet to be fully elucidated. Given its function as the major inhibitory neurotransmitter in the CNS, it is highly probable that behavioural symptoms associated with neurodegenerative diseases such as AD may be a direct or indirect result of GABAergic dysfunction. The role of GABA regarding such other important AD outcomes as cognition, disease progression, comorbidities (for example, weight loss), and mortality has not been evaluated. A new generation of GABAergic drugs with mechanisms of action not directly involving the GABA A receptor are currently being evaluated for various psychiatric indications. With this in mind, future research in this area is likely to realize the potential of GABAergic manipulation to improve symptoms among this population.
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